Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss drugs may turn back the biological clock, study hints

NCT ID NCT07444073

Knowledge-focused Sponsor: National University of Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study will follow 440 adults aged 40-89 who are starting a weight management program that includes drugs like semaglutide or tirzepatide along with lifestyle coaching. Researchers will measure changes in biological age using a blood-based aging clock over 6 months. The goal is to see if these treatments are linked to slower aging, not just weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide or tirzepatide
What this could lead to
If successful, this could show that common weight loss drugs may also slow the aging process, pointing toward new ways to extend healthy lifespan.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors like lifestyle changes, and the study is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 440 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 40-89 years who are overweight or obese and newly enrolled in the NOVI Health weight management program in Singapore. Participants are selected from routine clinical practice at the NOVI Health clinic.

Ages

40 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program. * BMI of ≥ 30 kg/m2 (obesity); OR * BMI of ≥ 27 kg/m2 to \< 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Exclusion Criteria * Pregnancy or lactation. * Non-ambulatory status, total blindness, complete hearing loss, or inability to speak. * Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes. * On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months. * Active cancer on chemotherapy or immunotherapy. * Known hypersensitivity or contraindications to GLP-1 RAs. * Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NOVI Health (T3 Health PTE LTD)

    Singapore, 068914, Singapore

  • National University of Singapore

    Singapore, 119077, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.